Objective. To investigate the effects of Compaximab and raizumab on retinal function and serum interleukin-17A level in retinopathy of prematurity. Methods. Sixty cases of retinopathy of prematurity treated in our hospital from February 2019 to April 2021 were selected. The patients were randomly divided into control group () and research group (). The control group was treated with Compaq and the research group was treated with razumab. The curative effect, retinal function, incidence of complications, intraocular pressure at different time, and the level of serum interleukin-17A were compared. Results. Compared with the two groups, the curative effect of the research group 93.33% (28/30) was greater than that of the control group 66.67% (20/30), and the difference was statistically significant (). Compared with the incidence of complications, the incidence of corneal opacity, lens opacity, preretinal and vitreous hemorrhage, endophthalmitis, and traction retinal detachment in the research group was greatly lower, and the difference was statistically significant (). Following the therapy, the IOP of the two groups decreased at different times. The IOP of 1 min, 10 min, and 30 min in the research group was obviously lower, and the difference was statistically significant (). Following treatments, the levels of serum IL-17A were decreased. Compared with the control group, the level of serum IL-17A in the research group was greatly downregulated, and the difference was statistically significant (). Conclusion. Intravitreal injection of razumab is an effective treatment for retinopathy of prematurity, which can effectively improve the retinal function of infants. The level of serum interleukin-17A can be reduced and intraocular pressure can be regulated, which is safe and effective.

中文翻译：

---

Combuxil和Leizumab对早产儿视网膜病变视网膜功能和血清白细胞介素17A的影响

客观的。探讨Compaximab和raizumab对早产儿视网膜病变视网膜功能和血清白细胞介素17A水平的影响。方法。选取2019年2月至2021年4月我院收治的早产儿视网膜病变患者60例。将患者随机分为对照组（）和研究组（）。对照组采用康柏治疗，研究组采用拉兹单抗治疗。比较两组患者的疗效、视网膜功能、并发症发生率、不同时间眼压、血清白细胞介素17A水平。结果。两组比较，研究组疗效93.33%（28/30）大于对照组66.67%（20/30），差异有统计学意义（）。与并发症发生率相比，研究组角膜混浊、晶状体混浊、视网膜前及玻璃体出血、眼内炎、牵拉性视网膜脱离的发生率均大大降低，差异有统计学意义（）。治疗后，两组的眼压在不同时间下降。研究组1 min、10 min、30 min眼压明显较低，差异有统计学意义（）。治疗后，血清IL-17A水平下降。与对照组相比，研究组血清IL-17A水平大幅下调，差异有统计学意义（）。 结论。玻璃体内注射razumab是治疗早产儿视网膜病变的有效方法，可有效改善婴儿视网膜功能。可降低血清白细胞介素17A水平，调节眼压，安全有效。